• Explore /
  • Poster
  • / Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

Abstract Poster

Authors

null

Petros Grivas

University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

Petros Grivas , Se Hoon Park , Eric Voog , Evgeny Kopyltsov , Howard Gurney , David Queiroz Borges Muniz , Frederic Rolland , Anne Birgitte Als , Begoña P. Valderrama , Jing Wang , Nuno Matos Costa , Robert J Laliberte , Alessandra Di Pietro , Thomas Powles , Joaquim Bellmunt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02603432

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4525)

DOI

10.1200/JCO.2021.39.15_suppl.4525

Abstract #

4525

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Srikala S. Sridhar

First Author: Begoña Pérez-Valderrama

First Author: Masatoshi Eto

First Author: Thomas Powles